Cargando…

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer

BACKGROUND: Neo-adjuvant chemotherapy (NaCT) facilitates complete surgical resection in locally advanced breast cancer. Due to its association with improved outcome, complete pathologic response (pCR) to neo-adjuvant treatment has been accepted as a surrogate for long-term outcome in clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soliman, Hatem, Wagner, Susanne, Flake, Darl D., Robson, Mark, Schwartzberg, Lee, Sharma, Priyanka, Magliocco, Anthony, Kronenwett, Ralf, Lancaster, Johnathan M., Lanchbury, Jerry S., Gutin, Alexander, Gradishar, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Breast Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000508/ https://www.ncbi.nlm.nih.gov/pubmed/31907749 http://dx.doi.org/10.1245/s10434-019-08039-7

Ejemplares similares

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
por: Soliman, Hatem, et al.
Publicado: (2019)

Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients
por: Curtis, Jeffrey R., et al.
Publicado: (2020)

Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes
por: Gallagher, Shannon, et al.
Publicado: (2020)

Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk
por: Hughes, Elisha, et al.
Publicado: (2020)

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer
por: Jin, Liang, et al.
Publicado: (2020)

Creating Neo-nipples with “Off the Shelf” Parts
por: Bender, Ryan, et al.
Publicado: (2021)

Single Center Oncoplastic Experience and Patient Satisfaction Reported via Patient Reported Outcomes
por: Wang, Xuanji, et al.
Publicado: (2022)

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Architecture distortion score (ADS) in malignancy risk stratification of architecture distortion on contrast-enhanced digital mammography
por: Goh, Yonggeng, et al.
Publicado: (2020)

Does Fitzpatrick Score Predict Flap Loss? Microsurgical Breast Reconstruction Outcomes of Varying Skin Color
por: Perez, Kevin, et al.
Publicado: (2022)

Impact of the Kaiser score on clinical decision-making in BI-RADS 4 mammographic calcifications examined with breast MRI
por: Wengert, G. J., et al.
Publicado: (2019)

Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ
por: Manders, Jennifer B., et al.
Publicado: (2016)

Correlation between MR Image-Based Radiomics Features and Risk Scores Associated with Gene Expression Profiles in Breast Cancer
Publicado: (2020)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams
por: Milos, Ruxandra Iulia, et al.
Publicado: (2020)

Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
por: Hassan, Saima, et al.
Publicado: (2022)

High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer
por: Crozier, Jennifer A., et al.
Publicado: (2021)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
por: Bardia, Aditya, et al.
Publicado: (2022)

Undiagnosed Patent Foramen Ovale and Thrombophilic Gene Mutations Resulting in Pulmonary Embolism with Cryptogenic Stroke after Cosmetic Breast Surgery
por: Zaussinger, Maximilian, et al.
Publicado: (2023)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

Scoring System to Predict Malignancy for MRI-Detected Lesions in Breast Cancer Patients: Diagnostic Performance and Effect on Second-Look Ultrasonography
Publicado: (2020)

An Argument for the Safety of Immediate Device Reconstruction following Mastectomy during the COVID-19 Crisis
por: Huang, Hao, et al.
Publicado: (2021)

Scoring System to Stratify Malignancy Risks for Mammographic Microcalcifications Based on Breast Imaging Reporting and Data System 5th Edition Descriptors
por: Youk, Ji Hyun, et al.
Publicado: (2019)

Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients
por: van der Velden, Bas H. M., et al.
Publicado: (2018)

Comparing the diagnostic efficacy of full field digital mammography with digital breast tomosynthesis using BIRADS score in a tertiary cancer care hospital
por: Singla, Divya, et al.
Publicado: (2018)

Prognosis Comparison Between Nipple-Sparing Mastectomy and Total Mastectomy in Breast Cancer: A Case-Control Study After Propensity Score Matching
por: Fu, Mengdie, et al.
Publicado: (2021)

Breast Reconstruction Trends in the Setting of Postmastectomy Radiation Therapy: Analysis of Practices among Plastic Surgeons in the United States
por: Khavanin, Nima, et al.
Publicado: (2023)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model
por: Gallagher, Shannon, et al.
Publicado: (2021)

Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy
por: Cuzick, Jack M., et al.
Publicado: (2021)

Validation of the NEOS score in Chinese patients with anti-NMDAR encephalitis
por: Peng, Yujing, et al.
Publicado: (2020)

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
por: Arboleda, Bolivar, et al.
Publicado: (2022)

Are There More HER2 FISH in the Sea? An Institution’s Experience in Identifying HER2 Positivity Using Fluorescent In Situ Hybridization in Patients with HER2 Negative Immunohistochemistry
por: Suydam, Camille, et al.
Publicado: (2023)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
por: Timms, Kirsten M, et al.
Publicado: (2014)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Differential Gene Expression in Capsules Derived From Smooth and Textured Silicone Implants
por: Daneshgaran, Giulia, et al.
Publicado: (2019)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6qkn8rgqomh72lljdc4ud2bl2s